Therapy Areas: Allergy
Moderna Receives Funding Award from CEPI to Accelerate Development of Messenger RNA Vaccine Against Novel Coronavirus
27 January 2020 - - US-based clinical stage biotechnology company Moderna, Inc., (NASDAQ: MRNA) has forged a new collaboration to develop an mRNA vaccine against the novel coronavirus (2019-nCoV), the...
Abionic Integrates First Patients in US Clinical Trial for Sepsis Diagnosis Method
13 January 2020 - - Swiss medtech firm Abionic SA is initiating a pivotal clinical trial in the US for an innovative point-of-care diagnostic method for sepsis to validate the results of a first trial...
ViiV Healthcare plans to develop N6LS
25 November 2019 - ViiV Healthcare, a global specialist HIV company majority owned by GSK, with Pfizer and Shionogi Limited as shareholders, is planning to develop the investigational broadly neutrali...
Savara Names Chowdhury as Chief Medical Officer
20 November 2019 - - US-based orphan lung disease company Savara Inc. (NASDAQ: SVRA) has appointed Badrul Chowdhury, M.D., Ph.D., to the newly created position of chief medical officer, effective imme...
BIOCORP partners with VITROBIO PHARMA to produce first drug treatment against allergy related to pollution
18 November 2019 - French medical company BIOCORP (FR0012788065 - ALCOR) said on Friday that it has entered into exclusive strategic partnership with VITROBIO PHARMA to tackle the global challenge of ...
Cosette Pharmaceuticals acquires G&W Laboratories' finished dosage manufacturing plant in Lincolnton, NC
4 November 2019 - Pharmaceutical company Cosette Pharmaceuticals Inc revealed on Monday that it has acquired G&W Laboratories' finished dosage manufacturing plant located in Lincolnton, NC, e...
Related Headlines

Aimmune Stock Trading Halted; FDA Allergenic Products Advisory Committee Meeting to Discuss Palforzia for Peanut Allergy

USFDA approves use of Aimmune Therapeutics' AR101

Crestone Secures NIH Funding for Phase 2 Clinical Trial of Novel Antibiotic Candidate

US FDA grants Breakthrough Therapy designation to Ridgeback Biotherapeutics' Ebola treatment

VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections

VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio

Signant Health names new clinical vice president, Internal Medicine

RTI International wins FDA approval for pretomanid for treating drug-resistant TB

First Patient Enrolled in CARES10, a Phase 3, Multi-Center Study to Assess a 10 % Intravenous Immunoglobulin in Adults with Primary Immunodeficiency Disease

Tivic Health announces USD8m from Series Seed Round

Dr. Reddy's Launches OTC, Store-Brand Equivalent of Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets in the US Market

LifeMax Receives Rare Pediatric Disease Designation for LM-030 for the Treatment of Netherton Syndrome

First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder

Dr. Reddy's Launches Over-the-Counter Store Brand Equivalent of Mucinex D Extended Release Tablets in Two Strengths in the US Market

CEL-SCI Collaborators Presents Data for New Vaccine in the Treatment of Rheumatoid Arthritis at the International Conference on Immunity and Immunochemistry Meeting